Literature DB >> 33169083

Genetic association between the rs12252 SNP of the interferon-induced transmembrane protein gene and influenza A virus infection in the Korean population.

Yong-Chan Kim1,2, Min-Ju Jeong1,2, Byung-Hoon Jeong1,2.   

Abstract

BACKGROUND: Interferon-induced transmembrane protein 3 (IFITM3) is a potent host antiviral effector protein that blocks the invasion of various viruses, including the influenza A virus (IAV). The C allele of the rs12252 single nucleotide polymorphism (SNP) shows vulnerability to the pandemic 2009 H1N1 IAV in European and Asian populations.
OBJECTIVE: Here, we estimated the disease susceptibility of the rs12252 SNP with the pandemic 2009 H1N1 IAV infection in the Korean population.
RESULTS: We carried out direct sequencing of the IFITM3 gene and compared the genotype and allele frequencies of the rs12252 SNP of the IFITM3 gene in healthy Koreans and pandemic 2009 H1N1 IAV-infected patients. Notably, we observed that healthy individuals had a similar genotype distribution of the rs12252 SNP (P = 0.140) as patients. The dominant model and recessive model did not find a statistically significant difference in genotype distribution between healthy individuals and patients. In addition, the allele distribution of the rs12252 SNP of in healthy individuals and patients also showed a similar genetic distribution (P = 0.757). However, the genetic distribution of rs12252 SNP in merged patient group (Koreans and Chinese populations) showed significant association with susceptibility of pandemic 2009 IAV (P = 0.0393).
CONCLUSION: To the best of our knowledge, this was the first evaluation of the susceptibility of the pandemic 2009 H1N1 IAV in the Korean population. © The Korean Society of Toxicogenomics and Toxicoproteomics 2020 2020.

Entities:  

Keywords:  Case–control study; IFITM3; Single nucleotide polymorphism; rs12252 SNP

Year:  2020        PMID: 33169083      PMCID: PMC7640581          DOI: 10.1007/s13273-020-00108-3

Source DB:  PubMed          Journal:  Mol Cell Toxicol        ISSN: 1738-642X            Impact factor:   1.080


Introduction

Interferon-induced transmembrane protein 3 (IFITM3) is a host antiviral effector protein that augments expression levels by type I and II interferons to respond to the invasion of various viruses, including influenza A virus (IAV) (Brass et al. 2009; Weidner et al. 2010; Bailey et al. 2012; Diamond and Farzan 2013; Kim et al. 2019; Lee et al. 2019). IFITM3 protein is localized in late endosomes and inhibits endosomal escape of influenza A viruses (Feeley et al. 2011). In particular, the N-terminal domain of the IFITM3 protein contains a sorting signal motif and plays a pivotal role in correct localization to the endosome and in blocking viral infections (Jia et al. 2012, 2014; Li et al. 2013). Recent studies showed that single nucleotide polymorphisms (SNPs) of the IFITM3 gene influence the antiviral capacity of the IFITM3 protein and are associated with the severity of the pandemic 2009 H1N1 IAV, which had a disastrous effect worldwide (van 't Klooster et al. 2010; Tramuto et al. 2011; Kim 2016). Among these SNPs, the C allele of the rs12252 SNP, which is located on the splicing receptor site, makes a 21 amino acid-shortened splicing isoform of the IFITM3 protein and shows susceptibility to the pandemic 2009 H1N1 IAV (Everitt et al. 2012). According to the 1000 genome database, although the European population has only 0.3% of the rs12252 SNP CC genotype, the CC genotype was found in 5.7% of hospitalized patients and showed a statistically significant association with the susceptibility to the pandemic 2009 H1N1 IAV. The correlation of the rs12252 SNP with the susceptibility to the severe pandemic 2009 H1N1 IAV was reaffirmed in Han Chinese populations, and there was a strong association between the number of intensive care unit patients and the rs12252 SNP CC genotype (Zhang et al. 2013; Lee et al. 2017). In addition, a case–control study in the Caucasian population identified an association of the rs12252 SNP with mild influenza infection (Mills et al. 2014). Previous study investigated the number of deaths from the pandemic 2009 H1N1 IAV and tried to find a correlation between the disease severity of influenza A virus infection and the rs12252 SNP; however, the study did not find an association of the rs12252 SNP with influenza severity (Kim and Jeong 2017). Although the relationship between influenza severity and rs12252 SNP was elusive (Lopez-Rodriguez et al. 2016), a cross-ethnic case–control study and a meta-analysis have validated the disease association of the rs12252 SNP with the pandemic 2009 H1N1 IAV (Xuan et al. 2015; Yang et al. 2015; Chen et al. 2018; Makvandi-Nejad et al. 2018; Prabhu et al. 2018). Several studies on ethnic groups have confirmed the relationship between the rs12252 SNP and the susceptibility to the pandemic 2009 H1N1 IAV, but an evaluation of the susceptibility to this virus in the Korean population has not been performed thus far. In the present study, we estimated the disease susceptibility of the rs12252 SNP with the pandemic 2009 H1N1 IAV infection in the Korean population. For this, we carried out direct sequencing of the IFITM3 gene and analyzed the genotype and allele frequencies of the rs12252 SNP of the IFITM3 gene between healthy individuals and pandemic 2009 H1N1 IAV-infected patients in Korea.

Materials and methods

Subjects

Thirty blood samples of laboratory-confirmed pandemic 2009 H1N1 IAV-infected patients were provided from the Jeonbuk National University Hospital Biobank, a member of the Korea Biobank Network. A total of 204 blood samples from healthy Korean subjects were obtained from the Korea Biobank Network at the Centers for Disease Control and Prevention. All samples derived from the Korea Biobank Network were obtained with informed consent under institutional review board-approved protocols. The exclusion criteria of healthy Koreans included diabetes, high blood pressure, gastritis, gastric ulcer, myocardial infarction, thyroid disease, congestive heart failure, coronary artery disease, hypothyroidism asthma, chronic lung disease, peripheral vascular disease, kidney disease, hepatitis, tuberculosis, cerebrovascular disease, head trauma, urinary tract infection, arthritis and cancer. All the samples and related data were anonymized prior to the analysis.

Genomic DNA extraction

Genomic DNA was extracted from 200 μl of blood using the Blood Genomic DNA Isolation Kit (Qiagen, Valencia, California, USA) following the manufacturer’s instructions.

Amplification of the IFITM3 gene and genetic analysis

The human IFITM3 gene was amplified from genomic DNA using forward and reverse gene-specific primers. The sequences of the primers were as follows: IFITM3-F (5′-CAGGGGAAGTCTCCAGGACC-3′) and IFITM3-R (5′-CCAAGCCACACACACACACA-3′). Polymerase chain reaction (PCR) was performed using GoTaq® DNA Polymerase (Promega, Fitchburg, Wisconsin, USA). The PCR mixture contained 20 pmol of each primer, 5 μl of 10 × Taq DNA polymerase buffer, 1 μl of 10 mM dNTP mixture and 2.5 units of Taq DNA polymerase. The PCR conditions of IFITM3-F and IFITM3-R primers were 94 °C for 2 min to denature; 35 cycles of 94 °C for 45 s, 71 °C for 45 s, and 72 °C for 1 min 30 s; and then 1 cycle of 72 °C for 10 min to extend the reaction. PCR was performed using S-1000 Thermal Cycler (Bio-Rad, Hercules, California, USA). The PCR products were purified using the PCR Purification Kit (Thermo Fisher Scientific, Bridgewater, New Jersey, USA) and directly sequenced with an ABI 3730 Automated Sequencer (ABI, Foster City, California, USA). Sequencing results were read by Finch TV software (Geospiza Inc, Seattle, Washington, USA), and genotyping was carried out.

Literature search

A literature search was conducted to looking for rs12252 SNP of the IFITM3 gene in previous studies. The searching terms were: “IFITM3”, “SNP”, “IAV” combined with “pandemic” or “susceptibility”. Moreover, we supplemented our search by screening the reference lists of the relevant studies, including the original article. References for all identified publications were indicated in Table 2.
Table 2

Genotype and allele frequencies of rs12252 SNP in healthy individuals and pandemic 2009 H1N1 Influenza A virus (IAV) affected patients in several populations

YearPopulationsTotalGenotype frequency, n (%)P valueaP valuebAllele frequency, n (%)P valuecP valuedHWERef
CCCTTTCT
Control
 2012YRIe591 (1.7)9 (15.3)49 (83) < 0.0001 < 0.000111 (9.3)107 (90.7) < 0.0001 < 0.00010.4530Everitt et al. (2012)
 2012CHBf/JPTg609 (15)18 (30)33 (55) < 0.0001 < 0.000136 (30)84 (70) < 0.0001 < 0.00010.0269
 2012CEUh/FINi/GBRj/IBSk/TSIl3601 (0.3)24 (6.7)335 (93) < 0.0001 < 0.000126 (3.6)694 (96.4) < 0.0001 < 0.00010.4218
 2013United Kingdom890 (0)2 (2.2)87 (97.8) < 0.0001 < 0.00012 (1.1)176 (98.9) < 0.0001 < 0.00010.9146Zhang et al. (2013)
 2013Northern Europe870 (0)7 (8.1)80 (91.9) < 0.0001 < 0.00017 (4)167 (96) < 0.0001 < 0.00010.6958
 2013Japanese8939 (43.8)35 (39.3)15 (16.9)0.05530.0420113 (63.5)65 (36.5)0.04700.62960.1521
 2013Han Chinese19750 (25.4)98 (49.7)49 (24.9)0.44420.0515198 (50.3)196 (49.7)0.21190.15940.9435
 2014GRACEm Control26234 (0.2)202 (7.7)2417 (92.1) < 0.0001 < 0.0001210 (4)5036 (96) < 0.0001 < 0.00010.9178Mills et al. (2014)
 2016Spanish2460 (0)17 (6.9)229 (93.1) < 0.0001 < 0.000117 (3.5)475 (96.5) < 0.0001 < 0.00010.5746López-Rodríguez et al. (2016)
 2017China20847 (22.6)105 (50.5)56 (26.9)0.14370.0353199 (47.8)217 (52.2)0.05020.07810.8682Lee et al. (2017)
 2018East Asian28686 (30.1)109 (38.1)91 (31.8)0.00580.0021281 (49.1)291 (50.9)0.08770.1090 < 0.0001David et al. (2018)
 2018Europe3790 (0)26 (6.9)353 (93.1) < 0.0001 < 0.000126 (3.4)732 (96.6) < 0.0001 < 0.00010.4893
 2018IBS140 (0)0 (0)14 (100) < 0.0001 < 0.00010 (0)28 (100) < 0.0001 < 0.0001NAp
 2018PGPn2000 (0)24 (12)176 (88) < 0.0001 < 0.000124 (6)376 (94) < 0.0001 < 0.00010.3667
 2018Africa24615 (6.1)89 (36.2)142 (57.7) < 0.0001 < 0.0001119 (24.2)373 (75.8) < 0.0001 < 0.00010.8324
 2018Central Africa14810 (6.8)58 (39.2)80 (54) < 0.0001 < 0.000178 (26.4)218 (73.6) < 0.0001 < 0.00010.9066
 –Korea20460 (29.4)103 (50.5)41 (20.1)0.1403223 (54.7)185 (45.3)0.43700.7901In this study
Case
 2012England and ScotlandTotal533 (5.7)4 (7.5)46 (86.8) < 0.0001 < 0.000110 (9.4)96 (90.6) < 0.0001 < 0.0001 < 0.0001Everitt et al. (2012)
 2013ChinaTotal8335 (42.2)39 (47)9 (10.8)0.05110.1993109 (65.7)57 (34.3)0.01550.43310.7019Zhang et al. (2013)
Severe3222 (68.8)8 (25)2 (6.2)0.00010.001752 (81.3)12 (18.7) < 0.00010.00920.3099
Mild5113 (25.5)31 (60.8)7 (13.7)0.38250.737457 (55.9)45 (44.1)0.82390.60880.0965
 2014GAinSo and GRACETotal2932 (0.7)25 (8.5)266 (90.8) < 0.0001 < 0.000129 (4.9)557 (95.1) < 0.0001 < 0.00010.1112Mills et al. (2014)
Severe340 (0)3 (8.8)31 (91.2) < 0.0001 < 0.00013 (4.4)65 (95.6) < 0.0001 < 0.00010.7878
Mild2592 (0.8)22 (8.5)235 (90.7) < 0.0001 < 0.000126 (5)492 (95) < 0.0001 < 0.00010.0790
 2016SpanishTotal1521 (0.7)18 (11.8)133 (87.5) < 0.0001 < 0.000120 (6.6)284 (93.4) < 0.0001 < 0.00010.6516López-Rodríguez et al. (2016)
Severe340 (0)5 (14.7)29 (85.3) < 0.0001 < 0.00015 (7.4)63 (92.6) < 0.0001 < 0.00010.6435
Mild1181 (0.9)13 (11)104 (88.1) < 0.0001 < 0.000115 (6.4)221 (93.6) < 0.0001 < 0.00010.4183
 2017ChinaTotal22484 (37.4)89 (39.9)51 (22.7)0.07490.0141257 (57.4)191 (42.6)0.42510.69820.0050Lee et al. (2017)
Severe2313 (56.5)6 (26.1)4 (17.4)0.03090.014632 (69.6)14 (30.4)0.05340.30880.0656
Mild20170 (35)84 (41.7)47 (23.3)0.21370.0236224 (55.7)178 (44.3)0.76070.53310.0300
 2018PortugueseTotal411 (2.5)6 (14.6)34 (82.9) < 0.0001 < 0.00018 (9.8)74 (90.2) < 0.0001 < 0.00010.2794David et al.( 2018)
Severe220 (0)4 (18.2)18 (81.8) < 0.0001 < 0.00014 (9.1)40 (90.9) < 0.0001 < 0.00010.6390
Mild191 (5.3)2 (10.5)16 (84.2) < 0.0001 < 0.00014 (10.5)34 (89.5) < 0.0001 < 0.00010.0545
 –KoreaTotal308 (26.7)20 (66.6)2 (6.7)0.140336 (60)24 (40)0.43700.0332In this study
Severe11 (100)0 (0)0 (0)0.49760.35482 (100)0 (0)0.50350.5177NA
Mild297 (24.1)20 (69)2 (6.9)0.13141.034 (58.6)24 (41.4)0.57010.87880.0232

P valuea: based on comparison of genotype frequencies with Korean control population

P valueb: based on comparison of genotype frequencies with Influenza A(H1N1) pdm09 Korean patients

P valuec: based on comparison of allele frequencies with Korean control population

P valued: based on comparison of allele frequencies with Influenza A(H1N1) pdm09 Korean patients

YRIe: Yoruba in Ibadan, Nigeria (African)

CHBf: Han Chinese in Beijing, China

JPTg: Japanese in Tokyo, Japan

CEUh: Utah residents with Northern and Western European ancestry from the CEPH collection (European)

FINi: Finns

GBRj: British

IBSk: IBERIAN populations in Spain

TSIl: Toscani

GRACEm: genomics to combat resistance against antibiotics in community acquired LRTI in Europe

PGPn: Portuguese general population

GAinSo: genomic advances in sepsis

NAp: not applicable

Genetic analysis

Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., USA). The differences in genotype and allele frequencies of the IFITM3 gene between case and control populations compared using χ2 test. The Hardy–Weinberg Equilibrium (HWE) test was performed using HWE calculator (https://www.genes.org.uk/software/hardy-weinberg.shtml).

Results

Subject description

A total of 234 individuals were included in the association analysis. Detailed information on the study population is described in Table 1. A total of 30 pandemic 2009 H1N1 IAV-diagnosed patients were composed of 19 females and 11 males. A total of 204 healthy individuals were composed of 130 females and 74 males. The mean age at diagnosis of 2009 H1N1 IAV-infected patients was 55.27 ± 17.88 years, and the mean age of healthy individuals at sample collection was 62.43 ± 8.96 years.
Table 1

The detailed information of the study population

CharacteristicsCasesControls
Number30204
Age55.27 ± 17.8862.43 ± 8.96
Sex (n, %)
 Male11 (36.67)74 (36.27)
 Female19 (63.33)130 (63.73)
The detailed information of the study population

Genotyping and HWE analyses

We performed direct sequencing in 204 healthy individuals and 30 pandemic 2009 H1N1 IAV-infected patients and carried out genotyping and HWE analyses. Detailed information on the genotyping results and HWE values in the Korean population is described in Table 2. Genotype and allele frequencies of rs12252 SNP in healthy individuals and pandemic 2009 H1N1 Influenza A virus (IAV) affected patients in several populations P valuea: based on comparison of genotype frequencies with Korean control population P valueb: based on comparison of genotype frequencies with Influenza A(H1N1) pdm09 Korean patients P valuec: based on comparison of allele frequencies with Korean control population P valued: based on comparison of allele frequencies with Influenza A(H1N1) pdm09 Korean patients YRIe: Yoruba in Ibadan, Nigeria (African) CHBf: Han Chinese in Beijing, China JPTg: Japanese in Tokyo, Japan CEUh: Utah residents with Northern and Western European ancestry from the CEPH collection (European) FINi: Finns GBRj: British IBSk: IBERIAN populations in Spain TSIl: Toscani GRACEm: genomics to combat resistance against antibiotics in community acquired LRTI in Europe PGPn: Portuguese general population GAinSo: genomic advances in sepsis NAp: not applicable

Evaluation of susceptibility of H1N1 influenza 2009 pandemic virus infection in the Korean population

To estimate disease the susceptibility of the rs12252 SNP of the IFITM3 gene with the pandemic 2009 H1N1 IAV in the Korean population, we performed a case–control association study. We observed that healthy individuals had a similar genotype distribution of the rs12252 SNP (P = 0.1403) to patients in the Korean population. Among 16 groups investigated in previous studies, the healthy Han Chinese population has a most similar distribution of rs12252 SNP with the healthy Korean population in genotype (P = 0.4442) and allele (P = 0.2119) frequencies (Table 2). We additionally tried to analyze association using the dominant model and recessive model in the Korean population.

Analyses in dominant and recessive models

To find risk factor on the susceptibility of pandemic 2009 H1N1 IAV infection in Korean population, two genetic models, including dominant and recessive models were performed in this study. In dominant model, the distribution of CC + CT and TT genotypes is 163 (79.9%) and 41 (20.1%) in control and 28 (93.3%) and 2 (6.7%) in case, respectively. The frequency of the CC + CT genotypes in pandemic 2009 H1N1 IAV-infected patients is substantially greater than that in the normal Korean population. However, the dominant model (P = 0.076) and the recessive model (P = 0.757) did not find a statistically significant difference in the genotype distribution between healthy individuals and patients (Table 3). In addition, the allele distribution of the rs12252 SNP in healthy individuals and patients also showed a similar genetic distribution (P = 0.437, Table 2).
Table 3

Association analysis in the dominant and recessive models in Korean population

Genetic modelControlCaseP value
Dominant model, n (%)
 CC + CT163 (79.9)28 (93.3)0.076
 TT41 (20.1)2 (6.7)
Recessive model, n (%)
 CC60 (29.4)8 (26.7)0.757
 CT + TT144 (70.6)22 (73.3)
Total, n20430
Association analysis in the dominant and recessive models in Korean population

Discussion

In the present study, we estimated the susceptibility of the rs12252 SNP to the pandemic 2009 H1N1 IAV in the Korean population. Interestingly, all genetic models performed in this study showed no correlation between the rs12252 SNP and the susceptibility of the pandemic 2009 H1N1 IAV in the Korean population. Further research is needed to assess whether this result is due to ethnic background. In addition, because it can be triggered by the small sample size of pandemic 2009 H1N1 IAV-infected patients in the Korean population, further study in a large population should be performed to validate the correlation between the rs12252 SNP and the susceptibility of the pandemic 2009 H1N1 IAV in the Korean population. However, there are severe limitations in this study due to small sample numbers of pandemic 2009 H1N1 IAV-infected patients and the impossibility of stratified study according to disease severity under current status of Korea biobank. Sample collection is systematically needed at the national level for preemptive control of pandemic diseases. Indeed, the mechanism of the antiviral capacity of the rs12252 SNP is elusive. Previous in vivo and in vitro studies failed to detect the 21 amino acid-shortened splicing isoform of the IFITM3 protein induced by the rs12252 SNP C allele (Makvandi-Nejad et al. 2018). In recent a study, the rs34481144 SNP, which is located on the promoter of the IFITM3 gene, showed an association with the severity of the pandemic 2009 H1N1 IAV (Allen et al. 2017; David et al. 2018). The rs34481144 SNP potently influenced the host innate immune system by modulating not only the expression level of the IFITM3 gene but also those of neighboring genes (Allen et al. 2017). In addition, the rs6598045 SNP was associated with the binding ability of the transcription factor of the IFITM3 gene and related to the susceptibility of the pandemic 2009 H1N1 IAV. T allele of rs6598045 SNP which is more prevalent in 2009 pandemic influenza-infected patients showed reduced promoter activity compared to C allele of rs6598045 which is more prevalent in healthy control (Kim et al. 2020). Because of the close genetic locus among the three SNPs, including rs12252 SNP, rs34481144 SNP and rs6598045 SNP, investigation of the relationship among them is highly desirable in the future. In conclusion, we investigated the genotype and allele frequencies of the rs12252 SNP of the IFITM3 gene and estimated the susceptibility of the pandemic 2009 H1N1 IAV in the Korean population. We found no correlation between the genotype, allele and dominant and recessive models of the rs12252 SNP and the vulnerability of the pandemic 2009 H1N1 IAV in the Korean population. To the best of our knowledge, this was the first evaluation of the susceptibility of the pandemic 2009 H1N1 IAV in the Korean population.
  26 in total

1.  SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans.

Authors:  E Kaitlynn Allen; Adrienne G Randolph; Tushar Bhangale; Pranay Dogra; Maikke Ohlson; Christine M Oshansky; Anthony E Zamora; John P Shannon; David Finkelstein; Amy Dressen; John DeVincenzo; Miguela Caniza; Ben Youngblood; Carrie M Rosenberger; Paul G Thomas
Journal:  Nat Med       Date:  2017-07-17       Impact factor: 53.440

2.  Association between IFITM3 rs12252 polymorphism and influenza susceptibility and severity: A meta-analysis.

Authors:  Suchitra S Prabhu; Trirupa Tapas Chakraborty; Nirmal Kumar; Indranil Banerjee
Journal:  Gene       Date:  2018-06-22       Impact factor: 3.688

3.  The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization.

Authors:  Rui Jia; Qinghua Pan; Shilei Ding; Liwei Rong; Shan-Lu Liu; Yunqi Geng; Wentao Qiao; Chen Liang
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

4.  No Correlation of the Disease Severity of Influenza A Virus Infection with the rs12252 Polymorphism of the Interferon-Induced Transmembrane Protein 3 Gene.

Authors:  Yong-Chan Kim; Byung-Hoon Jeong
Journal:  Intervirology       Date:  2017-08-17       Impact factor: 1.763

5.  Surveillance of hospitalised patients with influenza-like illness during pandemic influenza A(H1N1) season in Sicily, April 2009-December 2010.

Authors:  F Tramuto; C M Maida; F Bonura; A M Perna; S Puzelli; M A De Marco; I Donatelli; L Aprea; A Firenze; A Arcadipane; U Palazzo; F Vitale
Journal:  Euro Surveill       Date:  2011-09-01

6.  Surveillance of hospitalisations for 2009 pandemic influenza A(H1N1) in the Netherlands, 5 June - 31 December 2009.

Authors:  T M van 't Klooster; C C Wielders; T Donker; L Isken; A Meijer; C C van den Wijngaard; M A van der Sande; W van der Hoek
Journal:  Euro Surveill       Date:  2010-01-14

7.  IFITM3 inhibits influenza A virus infection by preventing cytosolic entry.

Authors:  Eric M Feeley; Jennifer S Sims; Sinu P John; Christopher R Chin; Thomas Pertel; Li-Mei Chen; Gaurav D Gaiha; Bethany J Ryan; Ruben O Donis; Stephen J Elledge; Abraham L Brass
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

8.  IFITM proteins restrict viral membrane hemifusion.

Authors:  Kun Li; Ruben M Markosyan; Yi-Min Zheng; Ottavia Golfetto; Brittani Bungart; Minghua Li; Shilei Ding; Yuxian He; Chen Liang; James C Lee; Enrico Gratton; Fredric S Cohen; Shan-Lu Liu
Journal:  PLoS Pathog       Date:  2013-01-24       Impact factor: 6.823

9.  Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals.

Authors:  Yong-Hong Zhang; Yan Zhao; Ning Li; Yan-Chun Peng; Eleni Giannoulatou; Rong-Hua Jin; Hui-Ping Yan; Hao Wu; Jin-Hua Liu; Ning Liu; Da-Yan Wang; Yue-Long Shu; Ling-Pei Ho; Paul Kellam; Andrew McMichael; Tao Dong
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  IFITM3, TLR3, and CD55 Gene SNPs and Cumulative Genetic Risks for Severe Outcomes in Chinese Patients With H7N9/H1N1pdm09 Influenza.

Authors:  Nelson Lee; Bin Cao; Changwen Ke; Hongzhou Lu; Yunwen Hu; Claudia Ha Ting Tam; Ronald Ching Wan Ma; Dawei Guan; Zhaoqin Zhu; Hui Li; Mulei Lin; Rity Y K Wong; Irene M H Yung; Tin-Nok Hung; Kirsty Kwok; Peter Horby; David Shu Cheong Hui; Martin Chi Wai Chan; Paul Kay Sheung Chan
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

View more
  3 in total

1.  Regulatory Single Nucleotide Polymorphism of the Bovine IFITM3 Gene Induces Differential Transcriptional Capacities of Hanwoo and Holstein Cattle.

Authors:  Yong-Chan Kim; Min-Ju Jeong; Byung-Hoon Jeong
Journal:  Genes (Basel)       Date:  2021-10-21       Impact factor: 4.096

2.  No Association between Single Nucleotide Polymorphisms (SNPs) of the Interferon-Induced Transmembrane Protein 3 (IFITM3) Gene and the Susceptibility of Alzheimer's Disease (AD).

Authors:  Sae-Young Won; Yong-Chan Kim; Byung-Hoon Jeong
Journal:  Medicina (Kaunas)       Date:  2021-12-30       Impact factor: 2.430

3.  The Role of Genetic Factors in the Development of Acute Respiratory Viral Infection COVID-19: Predicting Severe Course and Outcomes.

Authors:  Mikhail M Minashkin; Nataliya Y Grigortsevich; Anna S Kamaeva; Valeriya V Barzanova; Alexey A Traspov; Mikhail A Godkov; Farkhad A Ageev; Sergey S Petrikov; Nataliya V Pozdnyakova
Journal:  Biomedicines       Date:  2022-02-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.